ABIO - ARCA biopharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201612/31/201512/31/2014
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development12,3487,0635,625
Selling General and Administrative4,2654,3924,068
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-16,613-11,455-9,693
Income from Continuing Operations
Total Other Income/Expenses Net169147
Earnings Before Interest and Taxes-16,444-11,441-9,686
Interest Expense-43
Income Before Tax-16,444-11,445-9,689
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-16,444-11,445-9,689
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-16,444-11,445-9,689
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-16,444-11,445-9,689